Response rate, progression-free survival and overall survival to different treatment regimens for primary central nervous system (CNS) lymphoma.
| Study . | Number of Patients . | Regimen . | Response Rate (%) (CR and PR) . | Median PFS (mo) . | Median OS (mo) . |
|---|---|---|---|---|---|
| Abbreviations: PFS, progression-free survival; OS, overall survival; IT, intrathecal; MPV, methotrexate, procarbazine, vincristine; MTX, methotrexate; NA, not available; PFS, progression-free survival; WBRT, whole-brain radiotherapy. | |||||
| *After excluding patients with disease progression during radiotherapy, 26 patients were assessed by CT: 62% had a complete response (CR), 19% an almost CR and 19% a partial response. | |||||
| †patients over age 60 | |||||
| Radiotherapy alone | |||||
| Nelson et al 199212 | 41 | 40 Gy WBRT with 20 Gy boost | NA* | NA | 12.2 |
| Chemoradiotherapy | |||||
| Abrey et al 20001 | 52 | MPV (MTX 3.5g/m2), cytarabine (3 gm2) IT MTX ± 45 Gy WBRT | 94 | NA | 60 |
| Ferreri et al 200117 | 13 | MPV (MTX 3 g/m2) + 36–45 Gy WBRT with boost | 92 | NA | 25+ |
| DeAngelis et al 200214 | 102 | MPV (MTX 2.5 g/m2) + IT MTX + 36–45 Gy WBRT | 94 | 24 | 36.9 |
| Poortmans et al 200318 | 52 | MTX (3 g/m2)/teniposide/carmustine + IT MTX + IT cytarabine + 30 Gy WBRT with 10 Gy boost | 81 | NA | 46 |
| Omuro et al 200516 | 17 | MTX (1 g/m2)/thiotepa/procarbazine + IT MTX + 41.4 Gy WBRT with 14.4 Gy boost | 88 | 18 | 32 |
| Multidrug chemotherapy without radiotherapy | |||||
| Abrey et al 20001† | 22 | MPV (MTX 3.5 g/m2), cytarabine (3 g/m2), IT MTX | NA | NA | 33 |
| Pels et al 2003 23 | 65 | MTX (5 g/m2) + cytarabine (3 g/m2) + ifosfamide/vinca-alkaloids/cyclophosphamide + IT MTX + IT cytarabine | 71 | 21 | 50 |
| Hoang-Xuan et al 200322† | 50 | MTX (1 g/m2) + lomustine/procarbazine + IT MTX + IT cytarabine | 71 | 21 | 50 |
| MTX single agent | |||||
| Batchelor et al 200324 | 25 | MTX (8 g/m2) | 74 | 12.8 | 22.8+ |
| Herrlinger et al 2002, 200525,26 | 37 | MTX (8 g/m2) | 35.1 | 10 | 25 |
| Study . | Number of Patients . | Regimen . | Response Rate (%) (CR and PR) . | Median PFS (mo) . | Median OS (mo) . |
|---|---|---|---|---|---|
| Abbreviations: PFS, progression-free survival; OS, overall survival; IT, intrathecal; MPV, methotrexate, procarbazine, vincristine; MTX, methotrexate; NA, not available; PFS, progression-free survival; WBRT, whole-brain radiotherapy. | |||||
| *After excluding patients with disease progression during radiotherapy, 26 patients were assessed by CT: 62% had a complete response (CR), 19% an almost CR and 19% a partial response. | |||||
| †patients over age 60 | |||||
| Radiotherapy alone | |||||
| Nelson et al 199212 | 41 | 40 Gy WBRT with 20 Gy boost | NA* | NA | 12.2 |
| Chemoradiotherapy | |||||
| Abrey et al 20001 | 52 | MPV (MTX 3.5g/m2), cytarabine (3 gm2) IT MTX ± 45 Gy WBRT | 94 | NA | 60 |
| Ferreri et al 200117 | 13 | MPV (MTX 3 g/m2) + 36–45 Gy WBRT with boost | 92 | NA | 25+ |
| DeAngelis et al 200214 | 102 | MPV (MTX 2.5 g/m2) + IT MTX + 36–45 Gy WBRT | 94 | 24 | 36.9 |
| Poortmans et al 200318 | 52 | MTX (3 g/m2)/teniposide/carmustine + IT MTX + IT cytarabine + 30 Gy WBRT with 10 Gy boost | 81 | NA | 46 |
| Omuro et al 200516 | 17 | MTX (1 g/m2)/thiotepa/procarbazine + IT MTX + 41.4 Gy WBRT with 14.4 Gy boost | 88 | 18 | 32 |
| Multidrug chemotherapy without radiotherapy | |||||
| Abrey et al 20001† | 22 | MPV (MTX 3.5 g/m2), cytarabine (3 g/m2), IT MTX | NA | NA | 33 |
| Pels et al 2003 23 | 65 | MTX (5 g/m2) + cytarabine (3 g/m2) + ifosfamide/vinca-alkaloids/cyclophosphamide + IT MTX + IT cytarabine | 71 | 21 | 50 |
| Hoang-Xuan et al 200322† | 50 | MTX (1 g/m2) + lomustine/procarbazine + IT MTX + IT cytarabine | 71 | 21 | 50 |
| MTX single agent | |||||
| Batchelor et al 200324 | 25 | MTX (8 g/m2) | 74 | 12.8 | 22.8+ |
| Herrlinger et al 2002, 200525,26 | 37 | MTX (8 g/m2) | 35.1 | 10 | 25 |